Multiple Myeloma
The Challenge
A major global biopharmaceutical firm is in the process of developing a B-cell maturation antigen (BCMA) CD3-targeted bispecific antibody tailored for multiple myeloma. They seek DKI Health’s support to gain insights into the worldwide advocacy landscape, encompassing both conventional and unconventional stakeholders who influence treatment and care. A special focus is to address the gaps and challenges in education and access, especially among vulnerable, traditionally underserved patient populations.
Our Solution
Conducted a geographic disparity analysis by examining epidemiology data across regions to gain insights into the geographic distribution of populations disproportionately affected by multiple myeloma.
Performed comprehensive competitive intelligence to understand industry activities around advocacy, stakeholder engagement strategies, and remaining gaps.
Identified influential stakeholders, both traditional and non-traditional, for community relationship-building and early advocacy engagement.
Surveyed key stakeholders to understand key unmet needs and current challenges they face.
Developed advocacy engagement strategies to help address critical stakeholder challenges.
Led and facilitated multiple myeloma advocacy summits in United States, Europe, and Asia Pacific region.
Strengthened relationships with cancer patients to improve support for cancer care and treatment.
Advanced dialogues centered around enhancing support systems and resources for both patients and caregivers.
Benefit to Client
Improved Stakeholder Awareness: Knowledge of previously unknown and underserved but influential, non-traditional advocacy stakeholders.
Identification of Empowerment Gaps: Understanding of gaps and opportunity areas for empowering and assisting individuals grappling with multiple myeloma.
Enhanced Advocacy Insight: Better understanding of key advocacy influencers and their needs and challenges, specifically around addressing multiple myeloma.
Fortified Advocacy Relationships: Strengthened relationships with leading advocacy stakeholders to improve support available for multiple myeloma diagnosis, treatment, and care.
Innovative Stakeholder Engagement Strategy: A new forward-looking strategy for engaging with multiple myeloma advocacy stakeholders.